Why Eli Lilly Is This Analyst's 'New Top Large Cap Pick'

Tirzepatide has been de-risked and Eli Lilly And Co’s LLY Mounjaro could be the “biggest drug ever,” according to UBS.

The Eli Lilly Analyst: Colin Bristow upgraded Eli Lilly from Neutral to Buy while raising the price target from $335 to $363.

The Eli Lilly Takeaways: Mounjaro’s SURMOUNT-1 readout presented a best-in-class dataset with more than 20% weight loss and “several underappreciated metrics” that could drive peak sales to an estimated $25 billion, Bristow said in the upgrade note.

Check out other analyst stock ratings.

“We expect continued launch execution and, critically, FDA permitting filing in the obesity indication based solely on SURMOUNT-1, to serve as upside drivers of estimate,” the analyst said. 

While donanemab is risky, it is “the highest potential late-stage Alzheimer's asset, in our view, with LLY also being the best risk-reward play into BIIB's upcoming lecanemab read,” he added.

Lilly is the "new top large cap pick" at UBS, Bristow said. 

LLY Price Action: Shares of Eli Lilly were trading 3.59% higher at $307.11 Thursday morning. 

Photo via Shutterstock. 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesPrice TargetTop StoriesAnalyst RatingsColin BristowUBS
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!